177 related articles for article (PubMed ID: 32989607)
1. FRAMe: Familial Risk Assessment of Melanoma-a risk prediction tool to guide CDKN2A germline mutation testing in Australian familial melanoma.
Holland EA; Lo S; Kelly B; Schmid H; Cust AE; Palmer JM; Drummond M; Hayward NK; Pritchard AL; Mann GJ
Fam Cancer; 2021 Jul; 20(3):231-239. PubMed ID: 32989607
[TBL] [Abstract][Full Text] [Related]
2. Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT.
Taylor NJ; Mitra N; Qian L; Avril MF; Bishop DT; Bressac-de Paillerets B; Bruno W; Calista D; Cuellar F; Cust AE; Demenais F; Elder DE; Gerdes AM; Ghiorzo P; Goldstein AM; Grazziotin TC; Gruis NA; Hansson J; Harland M; Hayward NK; Hocevar M; Höiom V; Holland EA; Ingvar C; Landi MT; Landman G; Larre-Borges A; Mann GJ; Nagore E; Olsson H; Palmer JM; Perić B; Pjanova D; Pritchard AL; Puig S; Schmid H; van der Stoep N; Tucker MA; Wadt KAW; Yang XR; Newton-Bishop JA; Kanetsky PA;
J Am Acad Dermatol; 2019 Aug; 81(2):386-394. PubMed ID: 30731170
[TBL] [Abstract][Full Text] [Related]
3. MELPREDICT: a logistic regression model to estimate CDKN2A carrier probability.
Niendorf KB; Goggins W; Yang G; Tsai KY; Shennan M; Bell DW; Sober AJ; Hogg D; Tsao H
J Med Genet; 2006 Jun; 43(6):501-6. PubMed ID: 16169933
[TBL] [Abstract][Full Text] [Related]
4. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample.
Begg CB; Orlow I; Hummer AJ; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Mitra N; Busam K; From L; Berwick M;
J Natl Cancer Inst; 2005 Oct; 97(20):1507-15. PubMed ID: 16234564
[TBL] [Abstract][Full Text] [Related]
5. CM-Score: a validated scoring system to predict
Potjer TP; Helgadottir H; Leenheer M; van der Stoep N; Gruis NA; Höiom V; Olsson H; van Doorn R; Vasen HFA; van Asperen CJ; Dekkers OM; Hes FJ;
J Med Genet; 2018 Oct; 55(10):661-668. PubMed ID: 29661971
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome.
Lynch HT; Brand RE; Hogg D; Deters CA; Fusaro RM; Lynch JF; Liu L; Knezetic J; Lassam NJ; Goggins M; Kern S
Cancer; 2002 Jan; 94(1):84-96. PubMed ID: 11815963
[TBL] [Abstract][Full Text] [Related]
7. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents.
Goldstein AM; Chan M; Harland M; Hayward NK; Demenais F; Bishop DT; Azizi E; Bergman W; Bianchi-Scarra G; Bruno W; Calista D; Albright LA; Chaudru V; Chompret A; Cuellar F; Elder DE; Ghiorzo P; Gillanders EM; Gruis NA; Hansson J; Hogg D; Holland EA; Kanetsky PA; Kefford RF; Landi MT; Lang J; Leachman SA; MacKie RM; Magnusson V; Mann GJ; Bishop JN; Palmer JM; Puig S; Puig-Butille JA; Stark M; Tsao H; Tucker MA; Whitaker L; Yakobson E; ;
J Med Genet; 2007 Feb; 44(2):99-106. PubMed ID: 16905682
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling.
McWilliams RR; Wieben ED; Rabe KG; Pedersen KS; Wu Y; Sicotte H; Petersen GM
Eur J Hum Genet; 2011 Apr; 19(4):472-8. PubMed ID: 21150883
[TBL] [Abstract][Full Text] [Related]
9. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families.
Borg A; Sandberg T; Nilsson K; Johannsson O; Klinker M; Måsbäck A; Westerdahl J; Olsson H; Ingvar C
J Natl Cancer Inst; 2000 Aug; 92(15):1260-6. PubMed ID: 10922411
[TBL] [Abstract][Full Text] [Related]
10.
Pissa M; Helkkula T; Appelqvist F; Silander G; Borg Å; Pettersson J; Lapins J; Nielsen K; Höiom V; Helgadottir H
Acta Oncol; 2021 Jul; 60(7):888-896. PubMed ID: 33945383
[No Abstract] [Full Text] [Related]
11. Cancer risks and survival in patients with multiple primary melanomas: Association with family history of melanoma and germline CDKN2A mutation status.
Helgadottir H; Tuominen R; Olsson H; Hansson J; Höiom V
J Am Acad Dermatol; 2017 Nov; 77(5):893-901. PubMed ID: 28818438
[TBL] [Abstract][Full Text] [Related]
12. Surveillance of second-degree relatives from melanoma families with a CDKN2A germline mutation.
van der Rhee JI; Boonk SE; Putter H; Cannegieter SC; Flinterman LE; Hes FJ; de Snoo FA; Mooi WJ; Gruis NA; Vasen HF; Kukutsch NA; Bergman W
Cancer Epidemiol Biomarkers Prev; 2013 Oct; 22(10):1771-7. PubMed ID: 23897584
[TBL] [Abstract][Full Text] [Related]
13. Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study.
Demenais F; Mohamdi H; Chaudru V; Goldstein AM; Newton Bishop JA; Bishop DT; Kanetsky PA; Hayward NK; Gillanders E; Elder DE; Avril MF; Azizi E; van Belle P; Bergman W; Bianchi-Scarrà G; Bressac-de Paillerets B; Calista D; Carrera C; Hansson J; Harland M; Hogg D; Höiom V; Holland EA; Ingvar C; Landi MT; Lang JM; Mackie RM; Mann GJ; Ming ME; Njauw CJ; Olsson H; Palmer J; Pastorino L; Puig S; Randerson-Moor J; Stark M; Tsao H; Tucker MA; van der Velden P; Yang XR; Gruis N;
J Natl Cancer Inst; 2010 Oct; 102(20):1568-83. PubMed ID: 20876876
[TBL] [Abstract][Full Text] [Related]
14. CDKN2A germline alterations in melanoma patients with personal or familial history of pancreatic cancer.
De Unamuno B; García-Casado Z; Bañuls J; Requena C; Lopez-Guerrero JA; Nagore E
Melanoma Res; 2018 Jun; 28(3):246-249. PubMed ID: 29543703
[TBL] [Abstract][Full Text] [Related]
15. Early onset may predict G101W CDKN2A founder mutation carrier status in Ligurian melanoma patients.
Mantelli M; Pastorino L; Ghiorzo P; Barile M; Bruno W; Gargiulo S; Sormani MP; Gliori S; Vecchio S; Ciotti P; Sertoli MR; Queirolo P; Goldstein AM; Bianchi-Scarrà G;
Melanoma Res; 2004 Dec; 14(6):443-8. PubMed ID: 15577313
[TBL] [Abstract][Full Text] [Related]
16. Sporadic multiple primary melanoma cases: CDKN2A germline mutations with a founder effect.
Auroy S; Avril MF; Chompret A; Pham D; Goldstein AM; Bianchi-Scarrà G; Frebourg T; Joly P; Spatz A; Rubino C; Demenais F; Bressac-de Paillerets B;
Genes Chromosomes Cancer; 2001 Nov; 32(3):195-202. PubMed ID: 11579459
[TBL] [Abstract][Full Text] [Related]
17. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.
Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J
Cancer Res; 2000 Dec; 60(24):6864-7. PubMed ID: 11156381
[TBL] [Abstract][Full Text] [Related]
18. CDKN2A germline mutations in familial pancreatic cancer.
Bartsch DK; Sina-Frey M; Lang S; Wild A; Gerdes B; Barth P; Kress R; Grützmann R; Colombo-Benkmann M; Ziegler A; Hahn SA; Rothmund M; Rieder H
Ann Surg; 2002 Dec; 236(6):730-7. PubMed ID: 12454511
[TBL] [Abstract][Full Text] [Related]
19. Uptake of genetic counseling, genetic testing and surveillance in hereditary malignant melanoma (CDKN2A) in Norway.
Levin T; Mæhle L
Fam Cancer; 2017 Apr; 16(2):257-265. PubMed ID: 27804060
[TBL] [Abstract][Full Text] [Related]
20. CDKN2A germline mutations are not associated with poor survival in an Italian cohort of melanoma patients.
Dalmasso B; Pastorino L; Ciccarese G; Andreotti V; Grillo F; Mastracci L; Spagnolo F; Ballestrero A; Queirolo P; Bruno W; Ghiorzo P
J Am Acad Dermatol; 2019 May; 80(5):1263-1271. PubMed ID: 30274933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
